BENGALURU, Feb 13 (Reuters) - Alkem Laboratories' medical devices unit will buy up to a 55% stake in Switzerland's Occlutech Holding for 99.4 million euros ($118 million), the Indian pharma company ...

Alkem Laboratories reports 1.9% profit rise to ₹653.03 crore and plans to acquire 55% stake in Occlutech for €180.7 million.

Alkem Medtech to acquire a 55% stake in Swiss Occlutech for ₹1,074 crore, expanding into advanced cardiovascular devices.

Shares of Alkem Laboratories closed over 8% lower on the NSE on Friday, marking their steepest single-day fall since February 2025. The stock has now slipped below both its 50-day and 100-day moving ...

Alkem MedTech to acquire up to 55% stake in Switzerland-based Occlutech for €99.4 million, marking its entry into the global ...

The consensus estimate for Q3 2026 revenue is $37.60 billion, and the earnings are expected to come in at $57.50 per share. The full year 2026's revenue is expected to be $145.46 billion, and the ...

Based on the one-year price targets offered by 17 analysts, the average target price for Alkem Laboratories Ltd (NSE:ALKEM) is $5726.05 with a high estimate of $7225.00 and a low estimate of $4330.00.

For the latest installment in what’s become somewhat of a routine, European drug regulators are cracking down on data manipulation originating in India’s biopharma industry. This time, it’s Mumbai’s ...

BENGALURU, Feb 13 (Reuters) - Alkem Laboratories' medical devices unit will buy a stake of up to 55% in Switzerland's Occlutech Holding for 99.4 million euros ($118 million), the pharma company said ...

Alkem Laboratories' medical devices unit will buy a stake of up to 55% in Switzerland-based Occlutech Holding for 99.4 ...

Ltd on Friday reported a 1.9 per cent rise in consolidated net profit at Rs 653.03 crore in the third quarter ended December ...

Alkem Laboratories' medical devices unit will buy a stake of up to 55% in Switzerland-based Occlutech Holding for ...